Treatment Overview
Intravitreal Anti-VEGF Injection Therapy in Korea is a minimally invasive procedure that delivers vascular endothelial growth factor (VEGF) inhibitors directly into the vitreous cavity of the eye. This therapy reduces abnormal blood vessel growth, leakage, and retinal swelling, which are common in conditions such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and myopic choroidal neovascularization.
Korea is globally recognized for its advanced anti-VEGF programs, combining:
- Precision intravitreal injection protocols for safety and efficacy
- Use of FDA-approved VEGF inhibitors (e.g., Ranibizumab, Aflibercept, Bevacizumab)
- OCT-guided treatment planning to monitor retinal thickness and edema
- AI-assisted predictive modeling to optimize injection intervals
- Sterile, state-of-the-art injection suites minimizing infection risk
- Integrated follow-up imaging with OCT and fundus photography for outcome tracking
This therapy is a cornerstone in modern retinal care for preventing vision loss and improving visual outcomes.
Purpose & Benefits
Purpose
- Inhibit abnormal VEGF-driven blood vessel growth
- Reduce macular edema and retinal swelling
- Improve or stabilize visual acuity
- Prevent progression of wet AMD, DME, or RVO
- Serve as a first-line or adjunct therapy to laser or surgical interventions
- Enable precise, personalized treatment through imaging-guided planning
Benefits
- Minimally invasive outpatient procedure
- Rapid recovery and minimal downtime
- High efficacy in controlling macular edema and neovascularization
- OCT-guided therapy ensures accurate treatment monitoring
- Can be combined with other retinal procedures if necessary
- Reduces risk of permanent vision loss in chronic retinal diseases
- AI-assisted interval optimization may decrease injection frequency
Ideal Candidates
Intravitreal Anti-VEGF Therapy in Korea is suitable for:
- Patients with wet AMD or choroidal neovascularization
- Individuals with diabetic macular edema (DME)
- Patients with retinal vein occlusion (BRVO or CRVO) with macular edema
- Individuals with myopic CNV or other neovascular retinal conditions
- Patients showing progressive central vision loss due to VEGF-mediated pathology
- Postoperative patients requiring anti-VEGF adjunct therapy
Possible Risks & Complications
Intravitreal injections are generally safe but carry potential risks:
Common/Moderate Risks:
- Mild eye irritation or discomfort
- Temporary blurred vision
- Small subconjunctival hemorrhage (“red spot”)
- Mild intraocular pressure elevation
Rare/Serious Risks:
- Endophthalmitis (eye infection)
- Retinal detachment or tear
- Significant intraocular hemorrhage
- Allergic or systemic reaction to medication
- Vision loss in severe, rare cases
Korean clinics minimize risks through:
- Strict sterile injection protocols
- Pre- and post-injection OCT monitoring
- Experienced retinal specialists performing injections
- Emergency management protocols in case of adverse events
Related Treatment Techniques
- OCT-Guided Therapy – Determines edema and monitors response
- Fluorescein or Indocyanine Green Angiography – Identifies neovascular areas
- Fundus Photography & FAF – Tracks retinal changes
- Laser Therapy – Can be combined for refractory cases
- Combination with Vitrectomy – In select surgical cases
- Alternative Anti-VEGF Agents – Ranibizumab, Aflibercept, Bevacizumab
Treatment Process in Korea
Step 1 – Pre-Injection Assessment
- Comprehensive eye examination and OCT imaging
- Review of medical history, allergies, and systemic conditions
- Measurement of intraocular pressure and visual acuity
Step 2 – Injection Procedure
- Local anesthesia (eye drops or gel) applied
- Sterile preparation of the ocular surface
- Intravitreal injection of the selected anti-VEGF agent
- Immediate post-injection monitoring for adverse effects
Step 3 – Post-Injection Evaluation
- OCT imaging to assess retinal thickness and fluid reduction
- Visual acuity testing
- Intraocular pressure check
- Prescription of antibiotic or anti-inflammatory eye drops if indicated
Step 4 – Follow-Up & Maintenance
- Regular follow-up every 4–12 weeks, depending on treatment plan
- OCT-guided decision for repeat injections
- Long-term monitoring to prevent recurrence of edema or neovascularization
Duration: 10–20 minutes per injection
Setting: Advanced retinal clinic or ophthalmology center
Recovery & After-Care
After-Care Guidelines
- Avoid rubbing the eye for 24–48 hours
- Use prescribed eye drops as instructed
- Monitor for pain, redness, or sudden vision changes
- Attend all scheduled follow-up visits
Recovery Timeline
- Immediate: Mild blurred vision or discomfort
- 1–2 Days: Most symptoms subside, vision stabilizes
- 1–4 Weeks: OCT shows reduction in macular edema and improved retinal structure
- Long-Term: Continued injections may be required for chronic conditions
Results & Longevity
Expected Results
- Reduction of macular edema and retinal swelling
- Stabilization or improvement of visual acuity
- Slowed progression of wet AMD, DME, or RVO
- Improved quality of vision and daily functioning
Longevity
- Effects typically last 4–12 weeks per injection
- Long-term outcomes depend on adherence to treatment schedules
- Serial OCT monitoring ensures timely repeat injections for sustained vision preservation
Why Korea Is a Top Destination
- Highly experienced retinal specialists performing injections
- State-of-the-art OCT and imaging-guided treatment planning
- Access to all major FDA-approved anti-VEGF agents
- Efficient outpatient procedure with minimal downtime
- Personalized injection schedules optimized by AI and imaging data
- Comprehensive follow-up and multimodal retinal care
Unique Korean Innovations
- AI-assisted predictive modeling for optimal injection intervals
- OCT-guided real-time treatment response monitoring
- Combination protocols with laser, vitrectomy, or other retinal therapies
- Digital dashboards for long-term patient outcome tracking
- Personalized retinal care plans based on multimodal imaging
These innovations make Korea a global leader in Intravitreal Anti-VEGF Injection Therapy, offering precision treatment for complex retinal vascular conditions.
Cost Range (Indicative Estimate)
| Package | Price (KRW) | Approx. USD | Inclusions |
|---|---|---|---|
| Single Anti-VEGF Injection | ₩500,000 – ₩1,200,000 | ~$380 – $920 | Intravitreal injection + OCT follow-up |
| 3-Month Treatment Package | ₩1,400,000 – ₩3,000,000 | ~$1,100 – $2,300 | 3 monthly injections + OCT monitoring |
| 6-Month Intensive Package | ₩2,800,000 – ₩5,500,000 | ~$2,150 – $4,200 | 6 injections + OCT + follow-up |
| Combined Therapy (Injection + Laser/Imaging) | ₩3,500,000 – ₩6,000,000 | ~$2,700 – $4,600 | Anti-VEGF + OCT + optional laser or multimodal imaging |
Popular Clinics in Korea
- B&VIIT Eye Center (Seoul)
- Dream Eye Center (Seoul)
- BGN Eye Clinic (Seoul & Busan)
- Kim’s Eye Hospital (Seoul)
- Glory Seoul Eye Clinic
- NUNE Eye Hospital (Daegu)
- Seoul National University Hospital Retina Center
- Gangnam Severance Hospital Ophthalmology
